Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community
3 extracted signals · 2 resolved · 1 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 30 Jan 2026, 23:34 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
The pharmaceutical industry is facing pressure from the current administration to lower prices and increase access to medications. Despite this, three major companies – Pfizer, Novo Nordisk, and Eli Lilly – are identified as undervalued. Pfizer is trading at $25.60 with an intrinsic value of over $80. Novo Nordisk is trading at $62.53, with an intrinsic value of $82.64, and also has a first-to-market oral pill for weight loss. Eli Lilly is trading near its 52-week high at $1,068.97, with an intrinsic value of $1,600, and has shown exceptional performance. All three are rated as buy, with Eli Lilly being the top pick for 2026.
AI-generated summary based on the source content.
Signal outcomes at a glance
Partially ResolvedSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
3 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.